Cargando…

Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients

OBJECTIVE: To evaluate the long-term safety, tolerability, and efficacy of colesevelam HCl (colesevelam) in type 2 diabetes mellitus patients receiving metformin monotherapy or metformin combination therapy. METHODS: This post-hoc subgroup analysis examined data from type 2 diabetes mellitus patient...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bays, Harold E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395894/ https://www.ncbi.nlm.nih.gov/pubmed/22807633 http://dx.doi.org/10.2147/DMSO.S32018

Ejemplares similares

Effect of Colesevelam HCl Monotherapy on Lipid Particles in Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2014)

Safety and Efficacy of Colesevelam HCl in the Treatment of Elderly Patients
por: Gavin, James R., et al.
Publicado: (2014)

Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants
por: Lunven, Catherine, et al.
Publicado: (2017)

Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
por: Bays, Harold, et al.
Publicado: (2007)

Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record
por: Hansen, Richard A, et al.
Publicado: (2013)

Colesevelam‐induced hypoglycaemia in a patient with type 1 diabetes mellitus
por: Pavlou, Panagiotis, et al.
Publicado: (2021)

Glucose and Low-Density Lipoprotein Cholesterol Lowering in Elderly Patients with Type 2 Diabetes: Focus on Combination Therapy with Colesevelam HCl
por: Marrs, Joel C.
Publicado: (2012)

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
por: Fonseca, Vivian A., et al.
Publicado: (2008)

Colesevelam hydrochloride: A novel agent in patients with type 2 diabetes
por: Sekhri, Kavita, et al.
Publicado: (2011)

Atypical Mechanism of Glucose Modulation by Colesevelam in Patients with Type 2 Diabetes
por: Nwose, Oliseyenum M., et al.
Publicado: (2013)

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action
por: Zema, Michael James
Publicado: (2012)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
por: Fonseca, Vivian A, et al.
Publicado: (2010)

Role of Colesevelam in Combination Lipid-Lowering Therapy
por: Jones, Michael R., et al.
Publicado: (2013)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
por: Bays, Harold E
Publicado: (2014)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review
por: Bays, Harold Edward
Publicado: (2023)

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
por: Gallo, Silvina, et al.
Publicado: (2019)

Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study
por: Santova, Alzbeta, et al.
Publicado: (2023)

Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice
por: Cabré, Noemí, et al.
Publicado: (2021)

The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam
por: Kumar, Aditi, et al.
Publicado: (2023)

Long-term effects of metformin use in gestational diabetes mellitus on offspring health
por: Roy, Ayan, et al.
Publicado: (2021)

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52‐week open‐label, randomized phase III trial
por: Wang, Weiqing, et al.
Publicado: (2018)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
por: Bays, Harold
Publicado: (2013)

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
por: Kashiwagi, Atsunori, et al.
Publicado: (2011)

Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development
por: Zhou, Enchen, et al.
Publicado: (2020)

Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin
por: Jameshorani, Maryam, et al.
Publicado: (2017)

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
por: Frías, Juan P., et al.
Publicado: (2021)

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study
por: Yataba, Ikuko, et al.
Publicado: (2016)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_22ohp3l4i063pvpg1o3t805bd0